| Species |
Human |
| Protein Construction |
PAI-1 (Val24-Pro402)_x000D_
Accession # P05121-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit uPA cleavage of a peptide substrate, NcarbobenzyloxyGlyGlyArg7amido4methylcoumarin (ZGGRAMC). The IC50 value is < 35 nM. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
43.86 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 50mM NaAC, 0.1M NaCl, 100mM L-arginine (pH 5.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM NaAC, 0.1M NaCl, 100mM L-arginine (pH 5.5). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
PAI-1 (plasminogen activator inhibitor-1) is a member of plasminogen cascade with an inhibitory role in plasmin activation. PAI-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic protein are elevated in diabetes and insulin resistant states. |
| Synonyms |
PAI; PAI-1; Serpin E1; SERPINE1; PAI1; PLANH1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
